semaglutide amsterdam Poisoning reports linked to weight-loss injections in the Netherlands nearly doubled in just one year, and doctors are increasingly worried about where people are getting this medication from., The Weight-loss drug semaglutide shown to

Description

Beyond their effects on insulin secretion, GLP-1 agonists suppress glucagon release from pancreatic alpha cells, slow gastric emptying, and promote satiety through central nervous system pathways

While each medication has its own side effect profile, their concurrent use may create additive or synergistic risks

1 The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsA Long-Term Evaluation), a large double-blind, placebo-controlled trial, recently demonstrated that liraglutide added to standard therapy for a relatively short period of time (3.5-5 years) had a significant reduction in cardiovas-cular events and mortality compared to placebo in high-risk patients (hazard ratio [HR], 0.87